

Univ.-Prof. Dr. med Georg Heß
Department of Hematology, Oncology and Pneumology
University Medical School of the
Johannes Gutenberg-University
Langenbeckstr. 1
55101 Mainz
Germany

Tel.: 0049-(0)6131-17-5040
Fax: 0049-(0)6131-17-6678
E-mail: georg.hess@unimedizin-mainz.de

CURRICULUM VITAE

General Data

* 11.12.1966

University education

- Medicine - Mainz, New York, Idar-Oberstein, 1988-1994
- Thesis, 1996
- "Habilitation" - Venia legendi, 2007

Medical education

- 1994-2002: III. Department of Internal Medicine, Johannes Gutenberg-University, Mainz
- Specialty Internal Medicine, 2001
- Specialty Hematology/Oncology, 2002

Current position

- Head: Clinical Research Board of the UMM since 2017
- Full Professor of Medicine, Clinical experimental hematology and oncology since 2016
- Speaker: Working Party clinical trials of the UCT Mainz (CCC) since 2015
- Head of Study Department Hematology and Oncology since 07/2008
- Head Residency Program Hematology/Oncology since 2005
- Attending Physician III. Med. Department since 10/2003
- Lecturer: Key lectures internal medicine – lymphoma and multiple myeloma, Joined lectures: pathology/hematology

Memberships, Cooperative Boards and Board positions

- Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO), since 1998
- Subcommittee on Clinical Research, Auditor (DGHO), since 2015
- European Haematology Association (EHA), since 2005
- German Lymphoma Alliance (GLA), Secretary 2021+
- GLA - Working Party Mantle Cell Lymphoma, Speaker since 2019
- GLA - Working Party Early Trials, Speaker 2016-2019
- Prior Study Group activity (now all within GLA): GLSG, DSHNHL, ETN, since 1998

Clinical Trials

- „Prüfarzt für klinische Studien“(Clinical research scientist) since 1999, re-education 2019
- Continuous Education „Good Clinical Praxis“ since 1999
- Study Design of past and current investigator initiated clinical trials
- Leiter Klinische Prüfung (Coordinating principal investigator Germany), Principal Investigator or Subinvestigator in more than 100 clinical trials from phase I-IV since 1998

Current research projects

- Investigator initiated trials: GOAL-I (DLBCL), VIRAL (MCL), GOAL-II (DLBCL), EMCL-CAR-1 (MCL, activation)
- European Mantle Cell Lymphoma Registry, Coordinator, Sponsoring institution
- German Lymphoma Alliance-Registry, named Coordinator for pan-lymphoma registry
- Survivorship research, improved consenting in oncologic patients.

Reviewer for (sel)

- The Lancet, The Lancet Oncology, Haematologica, Leukemia, European Journal of Hematology, Leukemia and Lymphoma, Br. J. of Cancer, Annals of Hematology, Hematological Oncology, British Journal of Hematology, Bone Marrow Transplantation

Publications (rec | sel)

- Tilch MK, Visco C, Kinda S, Hermine O, et al., Outcome of COVID-19 in Patients With Mantle Cell Lymphoma- Report From the European MCL Registry. *Hemasphere*. 2022 Apr 8;6(5):e0711. doi: 10.1097/HS9.0000000000000711.
- Hess G, Hüttmann A, Witzens-Harig M, et al., A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial. *Br J Haematol*. 2022 Apr 1. doi: 10.1111/bjh.18161.
- Dreyling M, Goy A, Hess G, et al. Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up. *Hemasphere*. 2022 Apr 13;6(5):e712. doi: 10.1097/HS9.0000000000000712.
- Rieger K, De Filippi R, Lindén O et al., 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years. *Ann Hematol*. 2022 Apr;101(4):781-788. doi: 10.1007/s00277-022-04781-3.
- Balasubramanian S, Hodkinson B, Schuster SJ, et al. Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. *Cancer Med*. 2022 Jan;11(1):61-73. doi: 10.1002/cam4.4422.
- Tilch MK, Robak T, Ghiggi C, et al., Safety of the Anti-CD19 antibody Tafasitamab in Long Term Responders from A Phase II Trial for Relapsed Lymphoma. *Clin Lymphoma Myeloma Leuk*. 2022 Apr;22(4):270-275. doi: 10.1016/j.clml.2021.10.005.
- Witzens-Harig M, Viardot A, Keller U, Wosniok et al., The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatin (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial. *Hemasphere*. 2021 Sep 23;5(10):e636.
- Liebers N, Duell J, Fitzgerald D, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. *Blood Adv*. 2021 Jul 13;5(13):2707-2716. doi: 10.1182/bloodadvances.
- Freudenberger F, Ohler A, Theobald M, Hess G, Cure rate in the elderly patients with diffuse large B cell lymphoma deteriorates after the age of 80-results from a single-center survey. *Ann Hematol*. 2021 Apr;100(4):1013-1021. doi: 10.1007/s00277-021-04461-8.
- Morschhauser F, Bouabdallah K, Stilgenbauer S, et al: Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. *Haematologica*, 2020
- Hess G, Wagner K, Keller U, et al: Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma. *Hemasphere* 4:e398, 2020
- Rule S, Jurczak W, Jerkeman M, et al: Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. *Leukemia* 32:1799-1803, 2018
- Gopal AK, Schuster SJ, Fowler NH, et al: Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. *J Clin Oncol* 36:2405-2412, 2018
- Hess G, Rule S, Jurczak W, et al: Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. *Leuk Lymphoma*:1-9, 2017
- Viardot A, Goebeler ME, Hess G, et al: Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. *Blood* 127:1410-6, 2016
- Goebeler ME, Knop S, Viardot A, et al: Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. *J Clin Oncol* 34:1104-11, 2016
- Kirschey S, Flohr T, Wolf HH, et al: Rituximab combined with DEXA-BEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. *Br J Haematol* 168:824-34, 2015
- Hess G, Keller U, Scholz CW, et al: Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma. *Leukemia* 29:1695-701, 2015
- Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. *Lancet* 376:1164-1174, 2010
- Hess G, Herbrecht R, Romaguera J, et al: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. *J Clin Oncol* 27:3822-9, 2009
- Stolz C, Hess G, Hahnel PS, et al: Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. *Blood* 112:3312-21, 2008